Logo for Dancann Pharma

Dancann Pharma Investor Relations Material

Latest events

Logo for Dancann Pharma

Q4 2023

28 Feb, 2024
Logo for Dancann Pharma

Q3 2023

30 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Dancann Pharma

Access all reports
The company, through its subsidiary Kron Medical ApS, develops a portfolio of novel cannabinoid therapies on the basis of patented technology platforms in the areas of pain, cancer, and brain diseases/disorders. It is also developing medicines for the treatment of infantile spasms or seizures; and a class of drugs for the treatment of various conditions caused by redox signalling imbalance. The company was founded in 2015 and is based in Odense, Denmark